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ABSTRACT                        Heterotrimeric G-proteins are signal transducers of heptahelical receptors. They
consist of α and βγ subunits, both capable of interacting with several different effectors.
Specific domains in their structures enable them to connect different intracellular signaling
cascades, such as the adenylyl cyclase, phosphoinositol-bisphosphate or MAP kinase pathways.
Their activity is synchronized by several components, one of them being a new protein family
termed RGS (regulators of G-protein signaling). Members of this family inhibit the G-protein
function. The intracellular localization of G-proteins indicates their role in plasma membrane-
independent processes. Opioid receptors transmit their signals mainly via Gi/o proteins.
Although the heterogeneity of opioid ligands (peptides and alkaloids) and their receptors (µ,
δ, κ and suggested subtypes in these classes) reveals a complicated picture, their unique
characteristic of a high dependence capacity can not be explained without the analysis of the










General features of structure and function
The heterotrimeric guanine nucleotide binding proteins (G-
proteins) have been discovered about 20 years ago, and the
key nature of their participation in signal transduction led to
their discoverers being honored with the Nobel Prize for
medicine in 1994. They function as intermediaries in trans-
membrane signaling pathways that involve three proteins:
receptors, G-proteins, and effectors (Gilman 1987). They
belong in the superfamily of GTPases, which includes factors
that take part in protein synthesis (e.g. elongation factor Tu)
and small molecular weight (20-25 kDa) monomeric G-
proteins, such as p21 ras and its relatives (Hall 1990; Bourne
et al. 1990; Bourne et al. 1991; Kaziro et al. 1991). G-
proteins consist of three subunits, designated α, β and γ.
Traditionally, the type of the α subunit is used to define the
G-protein oligomer. To date, 23 distinct α subunits encoded
by 17 genes have been cloned with molecular masses be-
tween 39 and 46 kDa (Gudermann et al. 1997). They can be
divided into four subfamilies, Gs, Gi, Gq and G12, based on
amino acid sequence homology. Some of them are ubiqui-
tous, e.g. αs, while others are more or less specialized, for
example, αo for brain tissue or αt1 and αt2 for retinal rods and
cones, respectively. G-protein α subunits are enzymes with
inherent GTPase activity. They are also subject to several
cotranslational and posttranslational modifications. αi, αo and
αz are myristoylated at their N-terminus (Mumby et al.
1990); others are modified by different saturated or non-
saturated 12- and 14-carbon fatty acids, facilitating the
membrane attachment of α subunits and increasing their
affinity for βγ dimers (Linder et al. 1991). In addition to this
irreversible lipid modification, some α subunits, e.g. αs, are
reversibly palmitoylated on the cysteine residue nearest the
amino terminus, which seems to have a regulatory function
(Wedegaertner and Bourne 1994). While irreversible modifi-
cations are usually observed in the endoplasmic reticulum,
this reversible lipidation occurs in the cytoplasm. Upon
receptor activation, Gsα undergoes substantial depalmitoy-
lation, which may be further increased by cholera toxin.
Inactivation of the Gsα subunit is associated with repalmitoy-
lation, which inhibits the interaction of this subunit with other
regulatory proteins, e.g. Gα-interacting protein (GAIP). The
lipid sensitivity of the G-protein function implies also that the
lipid composition of the membrane microdomains can
influence the signaling (Green et al. 1999). A characteristic
modification of certain types of G-protein α subunits is the
ADP-ribosylation by bacterial toxins. Pertussis toxin catalyz-
es the covalent binding of ADP-ribose to a cysteine residue
located four amino acids from the C-terminus. All αo and αi
subunits can be modified in this way, resulting in uncoupling
from the receptor by inhibiting the activation of the α subunit.
Cholera toxin specifically ADP-ribosylates an arginine
residue in αt, αs and αolf, leading to inhibited GTPase activity,
that hence to constitutive activation of those α subunits
(Hepler and Gilman 1992). There are also several possible
sites for phosphorylation.
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Five β (35-37 kDa) and 12 γ (8 kDa) subunits have been
described to date (Watson et al. 1994; Ray et al. 1995;
Morishita et al. 1995). They are tightly associated and form
one functional unit. There is evidence that a degree of
specificity governs βγ dimer assembly, and not all possible
combinations are formed (reviewed in Gudermann et al.
1997). Gamma subunits are either farnesylated or geranylger-
anylated, which furnishes the anchorage to the plasma
membrane. It is generally considered that the β subunit
interacts with the α subunit, while the γ subunit determines
the effector specificity in the action of the dimer.
Role of G-proteins in signal transduction
Receptor-G-protein interaction
G-proteins serve as membrane-bound transducers of chemi-
cally and physically coded information. This extracellular
information is received by receptor (R) molecules that are
integrated plasma membrane proteins. Certain classes of such
receptors (e.g. ligand-gated ion channels or tyrosine kinase
receptors) themselves have effector domains, whereas others,
characterized by 7 transmembrane α helical domains (7TM
receptors or G-protein-coupled receptors, GPCRs), first
activate G-proteins, which in turn activate the effector
molecules. The steps in this cycle are presented in Fig. 1.
It is usually the third intracellular domain and the C-
terminal intracellular tail of the receptor molecule that
determine the R-G-protein interaction. For the activation of
G-proteins, Mg2+ and GTP are essential. Little is known
about the regulation of the GTPase cycle, since it proceeds
10 to 100 times faster in vivo than in vitro. However, several
proteins with GTPase-activating properties (GAPs) for Gα
subunits were recently described. They are termed regulators
for G-protein signaling (RGS; Watson et al. 1996). At least
20 different mammalian proteins have been reported to have
an RGS core, a common 120 amino acid domain. Although
the number of different Gα subunits is close to this, there is
not a one to one correspondence between them, and no RGS
specific for Gsα and G12α has so far been identified. The
GTPase-activating domain acts catalytically: a single mole-
cule of RGS can accelerate the GTPase activity of 4-6 Gα
subunits. They not only provide enhancement of the enzy-
matic activity for most of the Gα subunits, but may also
function as effector antagonists and integrators of different
signaling pathways, in consequence of their C- and N-
terminal protein binding motifs (Burchett 2000). One of them
is the GGL (G-protein gamma subunit-like) domain, which,
e.g. in human RGS11, has been shown to form a complex
with Gβ5 (Snow et al. 1998). The RGS11/Gβ5 complex is a
selective regulator of Goα.
G-proteins are also signal amplifiers. This can be
achieved at different levels. First, a single receptor can
activate several G-proteins in turn; second, the dissociation
of α and βγ subunits leads to bifurcation of the signal; and
on the third level, G-protein subunits can activate several
effector molecules before reassociation (Milligan 1996).
G-protein-effector interaction
Recent results show that, upon activation of a G-protein, both
α and βγ subunits are able to interact with different effectors
(Birnbaumer 1992) to induce further changes in the state of
the cell, leading to a response to the extracellular stimulus,
or, in a broader sense, to adaptation. The effectors and their
activator G-protein subunits are listed in Tables 1 and 2.
Influence of G-proteins on the gene expression
One main pathway for the regulation of gene expression by
extracellular signals transduced by GPCRs proceeds via the
activation of adenylyl cyclase and the subsequent production
of cyclic AMP (cAMP). cAMP regulates the transcription of
a variety of genes through a distinct DNA sequence termed
the cAMP response element (CRE), present in their promoter
regions. This element is recognized by the CRE-binding
protein (CREB), a transcription factor of 43 kDa. Activation
of CREB is achieved by cAMP-dependent protein kinase
Figure 1. Ligand-activated GTPase cycle of G-proteins. In the resting
state, heterotrimeric G-proteins bind GDP. The ligand-bound receptor
can activate the G-protein resulting in the exchange of GDP by GTP
and subsequent dissociation of α-GTP and the βγ dimer, each of them
capable of activating effectors. The effect is terminated by the
inherent GTPase activity of the α subunit and the reassociation of α-
GDP with βγ. R: receptor, A: agonist ligand.
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(PKA; Goodman 1990; Montminy et al. 1990; Collins et al.
1992; Zazopoulos et al. 1997)
The other pathway by which G-proteins can exert an
influence is the signaling route of the receptor tyrosine
kinases, such as epidermal growth factor, leading to cell
differentiation, proliferation and cytoskeletal effects through
the mitogen-activated protein kinase (MAPK) cascade. There
are several convergence points between the two signal
transduction pathways (for reviews, see Selbie and Hill 1998;
Seasholtz et al. 1999; Pierce et al. 2001).
Role of intracellular G-proteins
Heterotrimeric G-proteins are found not only in the plasma
membrane fractions, but also inside the cell, in the cytoplasm
or connected to the endomembrane systems such as the Golgi
and the endoplasmic reticulum. They can be detected in the
non-nervous tissues, such as the liver (Lanoix et al. 1989;
Toki et al. 1989), in the muscle (Carrasco et al. 1994) and also
in the brain (Bem et al. 1991; Holz and Tutner 1998).
These intracellular G-proteins can be newly synthesized
molecules, which are transported to the cell surface, probably
in a fully functional state, able to interact with receptors and
also with effectors (Zarbin et al. 1990; Vogel et al. 1991).
Intracellular G-proteins may also be conveyed from the cell
surface as part of the signal transduction process (Zarbin et
al. 1983; Laduron 1992; Szûcs and Coscia 1992). Several
plasma membrane receptors have a nuclear localization
signal in their cytoplasmic tail; accordingly, they, or part of
them, can enter the nucleus either alone or with other proteins
recruited during the signaling process (Laduron 1994).
However, recent results have revealed that G-proteins are not
only transported as passive molecules, but they also have
important intracellular functions. They have been suggested
to regulate various membrane trafficking processes, includ-
ing several steps of secretion. Coat assembly and the sorting
of newly synthesized proteins secreted constitutively in
polarized cells appear to be controlled by heterotrimer G-
proteins (Ktistakis et al. 1992; Robinson and Kreis 1992;
Pimplikar and Simons 1993). The processes of exocytotic
and endocytotic membrane fusion are also under the stimu-
latory control of Gi and the inhibitory control of Go (Bomsel
and Mostov 1992; Ahnert-Hilger et al. 1994; Colombo et al.
1994; Helms 1995). A role of G-proteins in the maintenance
of the highly specialized structure of the blood-brain barrier
has also been suggested (Brett et al. 1989; Hoyer et al. 1991;
Raub 1996; Fábián et al. 1998).
The opioid receptors
Opioid receptor types and function
Opioid receptors also belong in the family of GPCRs, and are
characterized by 7 hydrophobic transmembrane segments
and the ability to interact with different G-proteins (McKen-
zie and Milligan 1990; Offermanns et al. 1991; Laugwitz et
al. 1993). Opioid receptors have been identified in pharma-
cological studies through the use of peptide and alkaloid
ligands, and have been classified into three main classes, µ,
δ and κ (Martin et al. 1976). Cloning of the receptors has
verified this model (Kieffer et al. 1992; Evans et al. 1992;
Chen et al. 1993; Yasuda et al. 1993), but failed to prove the
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G-protein a subunits form 4 families based on sequence homology. * Splice variants. The data was taken from Weiland et al. (1997).
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existence of the opioid receptor subtypes proposed for all
three classes on the basis of pharmacological studies. This
suggests that the pharmacological subtypes may result from
posttranslational splicing modifications or differential
protein-protein interactions between receptors or with
associated proteins. The gene structures of all three opioid
receptors afford the possibility of alternative splicing, and
different mRNA products of single opioid receptor gene have
indeed been detected (Gaveriaux-Ruff et al. 1997; Schulz et
al. 1998). It has also been demonstrated that proteins encoded
by the mRNA isoforms of the µ opioid receptor are desensi-
tized at different rates (Koch et al. 1998). Extensive evidence
of pharmacological and functional interactions between
opioid receptor types has accumulated (reviewed by Jordan
et al. 2000). These studies show that heterodimers, such as
µ/δ, exhibit distinct ligand binding and signaling charac-
teristics. Additional signaling features and regulation occur
when δ or κ opioid receptors form heterodimers with β2-
adrenergic receptors (Jordan et al. 2001). This heterooli-
gomerization does not alter the ligand binding or coupling
properties of the receptors (although they couple to different
classes of G-proteins, i.e. Gi/o and Gs), but it affects their
trafficking. When coexpressed with β2 receptors, δ opioid
receptors undergo isoproterenol-mediated endocytosis.
Conversely, the β2 receptors in these cells undergo etorphine-
mediated endocytosis. However, the coexpression of κ opioid
receptors with β2 receptors blocks opioid- and isoproterenol-
mediated endocytosis. Ligand-specific regulation of the
endocytosis has been detected for homooligomers of the δ
receptor. Homodimer formation is reduced by increasing
concentrations of agonists, such as DADLE, DPDPE or
etorphine, while morphine is ineffective. Depolimerization
of the dimers correlated with the internalization of the
receptor (Cvejic and Devi 1997).
Pharmacological effects of the opioid receptors are listed
in Table 3.
Ligand binding to the opioid receptor
Radioligand binding studies combined with site-directed
mutagenesis of the receptor molecules have provided a great
deal of information on the interactions of opioid ligands with
their receptors (for a review, see Raynor et al. 1996). It is
thought that only agonist binding leads to activation of the
receptor, followed by conformational changes and infor-
mation transfer. In contrast, antagonist binding does not elicit
a biological response. Certain charged amino acids in the
transmembrane regions TM II (Asp114), III (Asp147) and VI
(His297) have been shown to be important for ligand binding
and subsequent activation of effectors (Surrat et al. 1994).
Further, opioid peptides and alkaloids, and also agonists and
antagonists bind to different parts of the receptor molecule
(Zastrov et al. 1993; Surrat et al. 1994). In the case of δ
receptors, the third extracellular loop is likewise important
for ligand selectivity (Quock et al. 1999). Identification of the
specific residues in the κ receptor involved in agonist and
antagonist binding may facilitate the further development of
therapeutically useful opioids since κ agonists have minimal
abuse potential and do not cause respiratory depression, two
major side-effects of the use of µ receptor-selective agonists.
Nonetheless, κ agonists are effective analgesics and useful
diuretic agents. Previous results have revealed that frog (Rana
esculenta) brain membranes are suitable for the investigation
of this opioid receptor type, since they contain a high
proportion of κ receptors as compared to µ and δ receptors
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(Simon et al. 1984). Frog brain membranes also contain κ
receptor subtypes, i.e. κ1 and κ2 (Benyhe et al. 1990; Wolle-
mann et al. 1993). A detailed characterization of these
binding sites in ligand binding studies indicated that they
might couple to G-proteins (Benyhe et al. 1991; Rottmann
et al. 1994; Bozó et al. 2000).
Another mode of investigation of ligand-receptor inter-
actions considers energetic aspects. Thermodynamic analysis
provides a means of determining the underlying driving
forces of binding and intermolecular interactions; such
information can not be easily obtained by other techniques.
Thus, conformational changes or protein-protein associations
should provoke characteristic thermodynamic behavior. With
this approach, it has been established that opioid agonist
binding is mainly entropy driven, while opioid antagonist
binding is exothermic, and therefore enthalpy driven (Nicolas
et al. 1982; Hintzemann et al. 1985; Zeman et al. 1987; Borea
et al. 1988; Fábián et al. 1996).
Opioid binding is modulated by a number of reagents.
Na+ and GTP decrease agonist binding without affecting
antagonist binding. Divalent cations also differentiate agonist
and antagonist binding (Szûcs et al. 1987; Benyhe et al. 1989
and references therein). These agents are also to be required
for the functional coupling of opioid receptors to inhibitory
G-proteins (Blume et al. 1979; Childers 1991; Johansson et
al. 1992). By means of thermodynamic investigations,
additional information can be expected about this signal
transduction step. Na+ or Mg2+ results only in quantitative
changes in the thermodynamic parameters. In the presence
of the GTP analog Gpp(NH)p, or Gpp(NH)p + Na+ or
Gpp(NH)p + Na+ + Mg2+, the affinity of dihydromorphine
binding decreases dramatically, which might reflect func-
tional uncoupling of the receptor-ligand complex and G-
proteins. These altered molecular interactions are also
indicated by the curvilinear van’t Hoff plot and entropy
increase (Fábián et al. 1996).
Consequences of repeated ligand
administration
The chronic use of opiates results in drug addiction, including
tolerance to and dependence on the drug; besides its scientific
importance, this phenomenon has a great social impact.
Despite intensive research in this field, the precise molecular
mechanism that accounts for it is unknown.
In biochemical terms, the long-term presence of the
agonist generally leads first to desensitization, which means
that the receptor is unable to activate effector molecules in
consequence of the uncoupling of the receptor from the
transducer G-protein. The reason for this is the phospho-
rylation of the receptor by specific kinases, such as β-
Table 3. Opioid receptor pharmacology
Receptor Biochemical effects Physiological effects




Ca2+ channel inhibition Immunosuppression
K+ channel stimulation
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Inhibition of cAMP accumulation Spinal analgesia
Inhibition of PI hydrolysis Diuresis, sedation
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Inhibition of cAMP accumulation
KOR-3/ORL-1 K+ channel stimulation Hyperalgesia (early)
Inhibition of cAMP accumulation Supraspinal analgesia (later)
δ Inhibition of cAMP accumulation Analgesia (spinal, supraspinal)
K+ channel stimulation Mouse vas deferens bioassay








The data was taken from Standifer and Pasternak (1997) with modifications. GH: growth hormone, GI: gastrointestinal, GPI: guinea pig ileum.
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adrenergic receptor kinase (βARK; Arden et al. 1995) or
calcium/calmodulin-dependent protein kinase II (Koch et al.
1997). This occurs on a minute time scale. Desensitization
is usually followed by sequestration and internalization of the
receptor into endosomal vesicles. This is still a minute to
hour-long procedure. Proteins in the endosomal vesicles can
be recycled to the cell surface or degraded in lysosomes. On
a longer time scale, down-regulation of the receptor can
occur, meaning reduction of the total (surface and intracel-
lular) receptor number. This certainly involves much more
complicated regulatory steps in the gene expression, transla-
tion and/or degradation of the certain protein. The above-
mentioned steps might give rise to the pharmacological
phenomenon of tolerance, meaning that the same dose of the
drug becoming ineffective in evoking a given response on
repeated administration, or conversely, an even larger dose
of drug is necessary to achieve the same magnitude of effect.
The term dependence refers more to physiological (or
somatic) and psychological aspects of addiction, the former
characterized by withdrawal symptoms on the cessation of
drug administration, and the latter by drug-seeking behavior.
The different anatomical correlates and molecular mecha-
nisms responsible for the opiate dependence have been
reviewed by Nestler (1992, 1994, 1996).
As mentioned above in the discussion of the possibility
of receptor oligomerization, opioid receptors are regulated in
a ligand-specific manner (Burford et al. 1998; Keith et al.
1998; Allouche et al. 1999; Li et al. 1999). For example, the
agonists DAMGO and endomorphin-1, but not morphine,
caused µ receptor internalization, even though they were
similar in activating individual G-proteins. Since endocytosis
is associated with functional desensitization of receptor-
mediated signal transduction, the differential effects of opiate
drugs on this regulatory mechanism may be of great physio-
logical importance. Whistler et al. (1999) suggest that the
ability of a drug to induce opioid receptor endocytosis is an
independent functional property of agonists, and they intro-
duce the RAVE factor (relative activity versus endocytosis)
as a measure of this. If the peptide agonist DAMGO is
defined as having a RAVE value of 1, morphine has an
approximately 4 times greater RAVE value, showing that its
relative ability to signal is much higher than its relative ability
to induce receptor endocytosis. They also hypothesized that,
in contrast with the prevailing hypothesis, the failure of
morphine-activated receptors to uncouple from G-protein and
endocytose appropriately might be responsible for the high
tolerance induced by this alkaloid.
However, not only receptors take part in the manifestation
of tolerance and dependence, but also other elements of the
signal transduction pathway. Although most emphasis has
been placed on analysis of the internalization and redistri-
bution of GPCRs, it has also been recognized that sustained
agonist treatment of cells can result in alterations in both the
cellular distribution and levels of G-proteins activated by the
relevant GPCR (Nestler et al. 1989; Terwilliger et al. 1991;
Van Vliet et al. 1993; Selley et al. 1997). Exposure of cells
to agonists of receptors linked to G-proteins can the result in
up- or downregulation of cellular levels or redistribution of
G-proteins from membranes to the cytosol. Agonist-induced
reductions in G-protein levels have been observed for
members of each of the Gs, Gi and Gq families of G-proteins,
are likely to be dependent upon the level of receptor ex-
pression or the brain area investigated, and are generally
restricted to the G-protein(s) with which the receptor inter-
acts. The mechanisms responsible vary with cell type and
include both second messenger-dependent and -independent
enhanced protein degradation. An agonist-induced reduction
in cellular G-protein levels can provide one mechanism for
the development of sustained heterologous desensitization
(for a review, see Milligan 1993). Selective upregulation of
certain G-proteins after chronic opioid treatment has also
been reported (Escriba et al. 1994; Manji et al. 1997). The
distinct pattern of changes in G-protein subtypes detected
after morphine administration might represent different
stages of the cellular adaptation to the continuous presence
of the drug and might reflect different roles of the G-protein
subtypes in this process. These data fit into the scheme of
drug regulation of neuronal gene expression suggested by
Nestler (1992, 1994), where one main group of genes target-
ed by the drug effect is that encoding G-proteins. The altered
gene expressions of several components of the cell signaling
system, such as adenylyl cyclase (Avidor-Reis et al. 1996;
Rivera and Gintzler 1998), protein kinase-C (PKC; Ventayol
et al. 1997), G-protein coupled receptor kinase (Ozaita et al.
1998) and protein phosphatases (Bernstein and Welch 1998),
contribute to the neuronal plasticity.
Conclusions
Data obtained by the use of molecular biological tools prove
that heterotrimeric G-proteins are not merely simple on/off
switches of effector functions, but also active integrators of
different intracellular processes. They provide several stages
for the fine-tuned regulation of the cellular functions induced
by different extracellular stimuli. The number of known
members of the RGS family will definitely increase rapidly
in the future, probably including proteins with effects
different from the activation of GTP hydrolysis. Having
several protein-protein interaction domains, G-proteins can
regulate the compositions of molecular complexes formed
after ligand-receptor activation, recruiting components
known previously to belong to separated signaling pathways.
As we begin to understand the detailed molecular mecha-
nisms involved in the signaling of opioid receptors, the
complexity is becoming increasingly evident. The hetero-
geneity of the receptors (µ, δ, κ and several subtypes in these
classes) and of the signal transducer G-proteins interacting
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with them is further complicated by the variety of down-
stream elements of different signaling cascades. This wide
array of interactions and regulatory effects might provide the
basis of the unique properties of the opioid ligands in
inducing heavy addiction in drug users. The clue to the
prevention of the manifestation of tolerance in the clinical use
of opioids or the successful therapy of opioid-dependent
patients lies in identification of the particular signaling
complexes implicated in the post-receptor events.
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